ARDD 2026 has announced that Alfredo Viegas, Managing Director, Emerging Markets Equity, at Oaktree Capital, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Alejandro Aguayo-Orozco, Ph.D., Senior Scientific Director, Diabetes Insights, at Novo Nordisk, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Jacqueline C.K. Lam, Ph.D., Chief Operating Officer and Co-Founder of ElohaX Ltd., will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

ARDD 2026 has announced that Ariel Feldstein, CSO of Internal Medicine at Pfizer, will speak at the 13th Aging Research & Drug Discovery (ARDD) Meeting, taking place October 1–3, 2026, at the David Rubenstein Treehouse at Harvard University. As the world's leading conference dedicated to longevity biotechnology, ARDD 2026 will convene top researchers, pharmaceutical executives, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines.

Organized by Insilico Medicine and supported by industry leaders including Eli Lilly and the McKinsey Health Institute, the meeting reflects the growing momentum behind longevity as a major frontier in biomedical innovation. With speakers representing ten of the world's leading pharmaceutical companies, ARDD 2026 aims to foster the collaborations needed to transform discoveries in aging biology into therapies that extend healthy lifespan and improve patient outcomes.

The University of Tennessee Herbert College of Agriculture has launched a new Bachelor of Science in Bioinformatics to prepare students to harness the power of big data, artificial intelligence, genomics and computational science to solve the world's greatest challenges.

Vanderbilt researchers have developed a new method for extracting intact cells from decades-old, formalin-fixed tissue samples, making it possible to use modern single-cell sequencing technologies on previously inaccessible samples. The approach could unlock vast archives of patient tissue, allowing scientists to study how diseases develop, why patients respond differently to treatments and potentially identify new biomarkers and treatment targets.

The foundation DKMS Stiftung Leben Spenden has opened the new application round for the DKMS John Hansen Research Grant. Up to four outstanding projects by early-career researchers worldwide will be funded, with each receiving up to €240,000 over a three-year period. The focus is on research projects related to hematopoietic stem cell transplantation and cell therapy for hematological diseases. Applications for the DKMS John Hansen Research Grant 2027 can be submitted through November 16, 2026.

One of the major challenges in glioma surgery is that tumor boundaries are often difficult to define. Diffuse gliomas can infiltrate surrounding brain tissue beyond what surgeons can see directly or what conventional imaging can fully resolve. During surgery, neurosurgeons must remove as much tumor as possible while preserving critical brain functions. This makes accurate intraoperative assessment of tumor infiltration essential for more precise surgical decision-making.  A study published in Cell now reports a new platform called ULTRA, short for ultrarapid cleared stimulated Raman with AI, designed to address this gap. Developed by researchers from Fudan University, Huashan Hospital of Fudan University, Zhongshan Hospital of Fudan University, Beijing Neurosurgical Institute, Capital Medical University, and collaborators, ULTRA combines rapid tissue clearing, stimulated Raman scattering microscopy, and AI-based virtual staining to perform deep 3D histological imaging of surgical tissue without conventional staining or sectioning.

Bone healing, an intricate process involving multiple cell populations, relies not only on existing bone-forming cells but also on dormant progenitor cells outside the skeleton. A study published in Bone Research reveals that fibroadipogenic progenitors (FAPs) in skeletal muscle become bone-forming cells after injury, contributing to fracture repair and abnormal bone growth. The findings identify these cells as promising therapeutic targets for enhancing fracture healing while preventing unwanted bone formation.